Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.
Kurashina R, Ando K, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y. Kurashina R, et al. Among authors: matsuoka y. Cancer Diagn Progn. 2023 Mar 3;3(2):230-235. doi: 10.21873/cdp.10206. eCollection 2023 Mar-Apr. Cancer Diagn Progn. 2023. PMID: 36875313 Free PMC article.
Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.
Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, Mitani K, Takenobu H, Haruta M, Onuki R, Matsuoka Y, Kamijo T, Kageyama Y. Ando K, et al. Among authors: matsuoka y. Biochem Biophys Res Commun. 2023 Oct 8;676:165-170. doi: 10.1016/j.bbrc.2023.07.054. Epub 2023 Jul 26. Biochem Biophys Res Commun. 2023. PMID: 37517219 Free article.
Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Kijima T, Yamamoto H, Saito K, Kusuhara S, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Sakai Y, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Kijima T, et al. Among authors: matsuoka y. Cancer Immunol Immunother. 2021 Mar;70(3):657-665. doi: 10.1007/s00262-020-02709-2. Epub 2020 Sep 2. Cancer Immunol Immunother. 2021. PMID: 32876736 Free PMC article.
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study.
Fukushima H, Kijima T, Fukuda S, Moriyama S, Uehara S, Yasuda Y, Tanaka H, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Matsubara N, Numao N, Sakai Y, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Fukushima H, et al. Among authors: matsuoka y. Cancer Med. 2020 Nov;9(22):8355-8363. doi: 10.1002/cam4.3445. Epub 2020 Sep 4. Cancer Med. 2020. PMID: 32886446 Free PMC article.
Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review.
Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Kijima T, et al. Among authors: matsuoka y. Clin Genitourin Cancer. 2021 Jun;19(3):208-216.e1. doi: 10.1016/j.clgc.2020.07.003. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32800718 Review.
Bimodal pattern of the impact of body mass index on cancer-specific survival of upper urinary tract urothelial carcinoma patients.
Ishioka J, Masuda H, Kijima T, Tatokoro M, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Saito K, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Yonese J, Kageyama Y, Noro A, Morimoto S, Tsujii T, Kitahara S, Gotoh S, Kihara K. Ishioka J, et al. Among authors: matsuoka y. Anticancer Res. 2014 Oct;34(10):5683-8. Anticancer Res. 2014. PMID: 25275074
2,060 results